Abstract
Pancreatic cancer (PC) is a malignant tumor with poor prognosis. The poor effect of surgery and chemotherapy makes the research of immunotherapy target molecules significant. Therefore, identifying the new molecular targets of PC is important for patients. In our study, we systematically analyzed molecular correlates of pancreatic cancer by bioinformatic analysis. We characterized differentially expressed analysis based on the TCGA pancreatic cancer dataset. Then, univariate Cox regression was employed to screen out overall survival- (OS-) related DEGs. Based on these genes, we established a risk signature by the multivariate Cox regression model. The ICGC cohort and GSE62452 cohort were used to validate the reliability of the risk signature. The impact of T lymphocyte-related genes from risk signature was confirmed in PC. Here, we observed the correlation between the T lymphocyte-related genes and the expression level of targeted therapy. We established a five-mRNA (LY6D, ANLN, ZNF488, MYEOV, and SCN11A) prognostic risk signature. Next, we identified ANLN and MYEOV that were associated with T lymphocyte infiltrations (P < 0.05). High ANLN and MYEOV expression levels had a poorer prognosis in decreased T lymphocyte subgroup in PC. Correlation analysis between ANLN and MYEOV and immunomodulators showed that ANLN and MYEOV may have potential value in pancreatic cancer immunotherapy.
Highlights
Pancreatic cancer is a malignant tumor with fewer than 7% of patients surviving the past 5 years [1]
The results showed that the expression of ANLN of Pancreatic cancer (PC) in decreased CD4+ memory T cells cohort had poorer overall survival (OS) and RFS, respectively (OS, log rank P = 3:4e − 05; RFS, log rank P = 1:5e − 05) (Figures 13(a) and 13(e)), But there was no significant correlation between the high ANLN and the prognosis of OS or RFS in the enriched CD4+ memory T cells (OS, log rank P = 0:32; RFS, log rank P = 0:077), respectively (Figures 13(b) and 13(f))
Our study revealed that the copy number alternations (CNAs) of ANLN and MYEOV significantly affected the CD4+ T cell infiltration level in PC by deleting and gaining aim level, providing insight into the TIME
Summary
Pancreatic cancer is a malignant tumor with fewer than 7% of patients surviving the past 5 years [1]. It has one of the worst outcomes among all cancers with a median survival of approximately 6 months [2]. Pancreatic cancer is forecast to be the second most common cancer in all malignant cancers by 2030 [3]. Common chemotherapy options for pancreatic ductal adenocarcinoma (PDAC) such as 5-fluorouracil (5FU), nab-paclitaxel, oxaliplatin, or combination therapy like FOLFIRINOX may lead to tumor resistance [4]. With the prevalence of chemotherapy resistance, immunotherapy may be an emerging treatment of pancreatic cancer. The effect of recent immune therapy trials was not Computational and Mathematical Methods in Medicine
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Computational and mathematical methods in medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
